{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-009485","form_type":"8-K","ticker":"ENVB","cik":"0000890821","company_name":"Enveric Biosciences, Inc.","filed_at":"2024-03-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:27.191408+00:00","generated_at":"2026-06-05T00:16:55.358847+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Enveric issues 228,690 shares for waiver of variable-rate limitation, enabling ATM facility","bullets":["Issued 228,690 common shares at $1.41/share to institutional investors; no proceeds to Enveric.","Investors permanently waive variable rate transaction limitation from Dec 28, 2023 inducement letters.","Waiver allows Enveric to utilize its 'at the market' offering facility with Canaccord Genuity.","Closing expected March 12, 2024; shares represent ~4.2% of outstanding (5.4M pre-offering)."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-009485","json":"https://secwatch.observer/filing/0001493152-24-009485.json","markdown":"https://secwatch.observer/filing/0001493152-24-009485.md","text":"https://secwatch.observer/filing/0001493152-24-009485.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/890821/000149315224009485/0001493152-24-009485-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/890821/000149315224009485/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T00:16:55.358847+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"07ce801b04e136b60f353099b8a039a6c51b50c5","claim":"Enveric Biosciences, Inc. entered into Purchase Agreement with certain institutional investors (effective 2024-03-08).","evidence_excerpt":"On March 8, 2024, Enveric Biosciences, Inc., a Delaware corporation (the “Company”) entered into a series of common stock purchase agreements (the “Purchase Agreement”) for the issuance in a registered direct offering of 228,690 shares of the Company’s common stock, par value $0.01 per share (the “Shares”), to certain institutional investors.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/890821/000149315224009485/0001493152-24-009485-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain institutional investors"},{"label":"Effective","value":"2024-03-08"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}